Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Initiatives
DHR logo

Danaher Reports 8% Biotechnology Growth Amid Strategic Portfolio Shifts

DHR10-KFiling Date: 2/24/2026
Danaher Corporation
Description

What this story covers

Danaher’s 2025 10-K highlights a 3% revenue increase driven by strong Biotechnology performance, despite Life Sciences stagnation and China headwinds. With $6.4 billion in operating cash flow, the company remains focused on strategic acquisitions and its Danaher Business System.

Story snapshot

CompanyDanaher Corporation
TickerDHR
VariantStandard detailed
Duration10:59
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000313616-26-000062
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in